Malignant Mesothelioma Market Report 2026

The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.61 billion in 2025 to $2.77 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to historical asbestos exposure in construction and manufacturing, long disease latency period, limited early treatment options, increasing occupational health awareness, gradual improvement in diagnostic imaging.

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancements in immunotherapy and targeted drugs, rising investment in rare cancer research, growing number of clinical trials, improved diagnostic technologies, increasing healthcare spending on oncology. Major trends in the forecast period include growing adoption of immunotherapy and targeted therapy, rising focus on multimodal treatment approaches, increasing demand for early and accurate diagnosis, expansion of specialized mesothelioma treatment centers, higher participation in clinical trials for rare cancers.

The growing clinical research and development efforts are anticipated to propel the growth of the malignant mesothelioma market in the coming years. Clinical research and development (R&D) efforts involve conducting scientific studies and trials to create new drugs, treatments, and medical devices. These efforts include evaluating the safety, effectiveness, and potential side effects of new products through controlled clinical trials. The rise in clinical research and development activities is driven by the increasing demand for novel and improved treatments, particularly due to the growing prevalence of chronic diseases and complex medical conditions. Research and development efforts advance malignant mesothelioma by facilitating progress in diagnostics, therapies, and targeted treatments, promoting innovative strategies to enhance early detection, improve survival rates, and develop more effective and less invasive treatment options. For example, in January 2025, Anadolu Agency, a Turkey-based state-run news agency, reported that clinical trials account for nearly 40% of the U.S. pharmaceutical research budget, amounting to approximately $7 billion annually. Consequently, the expanding research and development efforts are fueling the growth of the malignant mesothelioma market.

Major companies operating in the malignant mesothelioma market are concentrating on developing advanced treatment options, such as monoclonal antibody therapies, to inhibit tumor growth and enhance treatment precision. Monoclonal antibodies are laboratory-engineered proteins that replicate the immune system's ability to recognize and target specific antigens, including those present on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody, for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval introduces Opdivo as a new treatment option for this condition, where no standard therapies were previously established. Opdivo was granted orphan drug designation for this indication, emphasizing its potential to meet a significant medical need.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. Through this acquisition, AstraZeneca will obtain all of Gracell's fully diluted share capital, including shares represented by American depositary shares. Gracell Biotechnologies, based in China, specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.

North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malignant mesothelioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have had a moderate impact on the malignant mesothelioma market by increasing the cost of imported oncology drugs, immunotherapies, and advanced radiation equipment. Treatment segments such as immunotherapy and targeted therapy are most affected, especially in regions reliant on imported pharmaceuticals like asia-pacific and parts of europe. Higher tariffs may slow adoption of advanced treatments due to pricing pressures. However, tariffs have encouraged domestic manufacturing and local research collaborations, supporting long-term market stability.

The malignant mesothelioma market research report is one of a series of new reports that provides malignant mesothelioma market statistics, including malignant mesothelioma industry global market size, regional shares, competitors with a malignant mesothelioma market share, detailed malignant mesothelioma market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. This malignant mesothelioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malignant mesothelioma is an uncommon and aggressive form of cancer that primarily targets the mesothelium, a thin layer of tissue that surrounds most internal organs. It most frequently develops in the lining of the lungs (pleura) but can also appear in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The primary risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral that was once extensively used in construction and manufacturing.

The main treatment approaches for malignant mesothelioma include chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy for malignant mesothelioma involves using drugs to destroy cancer cells, slow tumor progression, and help manage symptoms. It is often employed when the cancer has spread beyond the area where surgery alone would be effective. The routes of administration include oral, intravenous, injectable, and topical methods. The distribution channels involved are hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which are utilized by hospitals, oncology clinics, rehabilitation centers, and research laboratories.

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.